CTC Bio, a pharmaceutical research and development company (CEO: Min-gu Lee), announced on the 29th that global supply based on the global supply contract for ‘CTCzyme’ signed in June has officially begun.
As part of the contract between CTC Bio and the global animal pharmaceutical giant HUVEPHARMA, signed in June, it was revealed that a major global feed company in the United States has started feeding trials to use ‘CTCzyme’.
A company official stated, “The feeding trials are currently underway in full swing, and we expect to receive the results quickly and proceed with full-scale delivery,” adding, “Since HUVEPHARMA has established various global sales channels in the US, India, Brazil, and other countries, we expect many such supplies to be made in the future.”
‘CTCzyme’ is a feed digestive enzyme developed using CTC Bio’s proprietary fermentation technology, making it the first of its kind in Asia and the second worldwide. It maximizes the digestion and absorption of nutrients in livestock consuming the feed, promotes a healthy gut microbiome, and strengthens intestinal immunity, attracting significant interest from many feed companies.
Min-gu Lee, CEO of CTC Bio, said, “It is highly meaningful that a global major feed company is conducting feeding trials to use ‘CTCzyme,’ and we anticipate that positive trial results will enable delivery within this year,” adding, “We will continue to do our best to enhance corporate value by proving growth potential through stable management and continuous performance improvement.”
Meanwhile, CTC Bio plans to actively respond to the increasing global supply demand and establish a stable management system to enhance shareholder value through performance growth. Under a stable management system, the company intends to further strengthen the current management structure through additional share purchases and securing friendly shares to focus more on smoothly operating businesses.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
